Retatrutide, a groundbreaking dual-acting glucose-responsive incretin mimetic, represents a significant progression in peptide treatments for the treatment of type 2 diabetes and, increasingly, excess adiposity. Unlike many existing medicinal interventions, retatrutide combines the actions of a GLP-1 receptor stimulant and a GIP receptor stimulant,